cagrilintide vs retatrutide retatrutide: amylin analogue vs triple agonist compared Cagrilintide and Retatrutide: Why Most

Right tool for right job based on mechanism-pathology matching

Most common side effects were gastrointestinal, with 24.5% of participants in the phase 2 obesity trial discontinuing efinopegdutide 10 mg due to AE however when the same dose was used with gradual escalation at the MASLD trial (starting dose 2.4 mg for 4 weeks, then 5 mg for 4 weeks and then 10 mg), only 5.6% of participants discontinued the medication due to AE

doi: 10.1016/s1470-2045(13)70104-9 21 WhiteSSBirnbaumLS

Future research will determine whether GLP-1 drugs can become a mainstay in treating neurological and psychiatric conditions alongside traditional therapies

Bimagrumab, a monoclonal antibody targeting activin type II receptors, has shown potential to increase lean mass while reducing fat mass

Wolfe RR